Ark Biosciences

Aspiring To Be Mighty In the earliest years of this century, I was asked by a colleague based in Scotland for 3i Group, to attend a conference there for a second opinion on a biotech company headlini

Virology-focused Enanta Pharmaceuticals, Inc. took a positive step in its two-mechanism approach to providing a treatment for respiratory syncytial virus (RSV) on 26 September as its RSV L-protein i

Amid a sweeping tightening of securities regulatory policies since late 2023, there has been a dearth of initial public offerings for bioventures in the Chinese mainland. But Hong Kong has just welcom

Chinese biotechs once aspired to launching their products in the US and listing on Nasdaq as their ultimate achievements, but now many are turning more attention to their home turf and the Shanghai St